Basal VEGF-A and ACE Plasma Levels of Metastatic Colorectal Cancer Patients Have Prognostic Value for First-Line Treatment with Chemotherapy Plus Bevacizumab

SIMPLE SUMMARY: Molecular biology knowledge has enabled the incorporation of targeted therapies, such as the anti-angiogenic drug bevacizumab, into combined chemotherapy regimens for the treatment of metastatic colorectal cancer. However, to date, there are no reliable useful biomarkers to predict t...

Descripción completa

Detalles Bibliográficos
Autores principales: Ortiz-Morales, M. José, Toledano-Fonseca, Marta, Mena-Osuna, Rafael, Cano, M. Teresa, Gómez-España, Auxiliadora, la Haba-Rodríguez, Juan R. De, Rodríguez-Ariza, Antonio, Aranda, Enrique
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9265004/
https://www.ncbi.nlm.nih.gov/pubmed/35804826
http://dx.doi.org/10.3390/cancers14133054

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9265004/
https://www.ncbi.nlm.nih.gov/pubmed/35804826
http://dx.doi.org/10.3390/cancers14133054

Ejemplares similares